Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer

Nucl Med Commun. 2013 Nov;34(11):1084-9. doi: 10.1097/MNM.0b013e328364eaab.

Abstract

Background: Somatostatin receptor (Sstr) scintigraphy with radiolabelled somatostatin analogues has been used extensively for the diagnosis and therapy of Sstr-expressing tumours. It has been shown that well-differentiated thyroid cancer (WDTC) cells have a high expression of Sstr2, Sstr3 and Sstr5. Hence, WDTC cells could be an ideal target for the evaluation of lesion uptake of Ga-68 DOTA-1-NaI3-octreotide (DOTA-NOC), which has a high affinity not only to Sstr2 but also to Sstr3 and Sstr5. The aim of the present study was to evaluate the value of Ga-68 DOTA-NOC as a target for Sstr2-expressing, Sstr3-expressing and Sstr5-expressing tumours in WDTC patients and to compare the results with those of Ga-68 DOTA-TATE in the same patient population.

Method: Thirteen patients with WDTC were included in our study: nine with papillary thyroid cancer, three with Hurthle cell carcinoma and one with follicular thyroid carcinoma. All patients had elevated serum thyroglobulin levels and negative post-therapeutic I-131 whole-body scans, which were obtained after the last radioiodine treatment. All patients had undergone two consecutive PET imaging studies with Ga-68 DOTA-D-Phe1-Tyr3-octreotate (DOTA-TATE) and Ga-68 DOTA-NOC, respectively. All images were evaluated visually, and maximum standardized uptake values were calculated.

Results: Both Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET images gave comparable results. Among the 13 patients, imaging with both Ga-68 DOTA-TATE and Ga-68 DOTA-NOC gave negative results in five (38%) patients and positive results in eight (62%) patients. A total of 45 lesions were identified on Ga-68 DOTA-TATE images and 42 on Ga-68 DOTA-NOC images; three lesions were missed. Lesion uptake was significantly higher on Ga-68 DOTA-TATE images. Maximum standardized uptake values of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC were 12.9±9.1 and 6.3±4.1 (n=54, P<0.001), respectively.

Conclusion: Our study suggested that Ga-68 DOTA-TATE has a higher lesion uptake even in WDTC patients and may have potential advantage over Ga-68 DOTA-NOC.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Follicular / diagnostic imaging*
  • Adenoma, Oxyphilic
  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal
  • Carcinoma / diagnostic imaging*
  • Carcinoma, Papillary
  • Female
  • Gallium Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Octreotide
  • Organometallic Compounds
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms / diagnostic imaging*
  • Tomography, X-Ray Computed / methods*

Substances

  • 68Ga-DOTANOC
  • Antineoplastic Agents, Hormonal
  • Gallium Radioisotopes
  • Organometallic Compounds
  • Radiopharmaceuticals
  • gallium Ga 68 dotatate
  • Octreotide

Supplementary concepts

  • Thyroid cancer, Hurthle cell